Envista Holdings Corp (NVST) - Stock Analysis
Last updated: Apr 6, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Envista presents strong Q4 2025 beats, positive analyst upgrades, a raised full-year guidance, robust institutional buying, and a ~24% price gain with breakout above 21-day SMA, supported by product momentum in implants and imaging, though tariff and macro risks temper short-term certainty.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High gross margin ⢠Strong FCF ⢠Low net profitability NVST pairs strong gross margins, robust free cash flow and healthy liquidity with moderate leverage but is hampered by low net profitability, large intangibles and a stretched valuation. â
Price Behavior
Key Price Behavior Insights: ⢠Modest downtrend ⢠Price consolidation ⢠Failed retake Support Level: $24.26 Resistance Level: $27.90 Over the last month NVST drifted modestly lower from the March 5 high to the April 2 close (mid-single-digit decline), consolidating around the short-term average with resistance near $27.90 and support near $24.26.
Sentiment & News
Key News Insights: ⢠Zacks Rank ⢠42.5% gain ⢠Institutional sale Envista (NVST) is receiving converging bullish signalsâZacks Rank #1 and analyst upgrades, strong 42.5% Y/Y share gains and technical/earnings upgradesâoffset slightly by an 8.2% institutional sell-off.
AI Summary
Envista should be reârated not as a steady hardware grower but as an operationalâimprovement play where Spark reaching profitability plus $1.2bn+ cash and $35m G&A cuts create a credible pathway to meaningful margin expansion and FCF â but upside is tightly contingent on sustaining Spark scale without marketing inflation and avoiding impairments or reimbursement/distribution shocks that would quickly reverse the current premium.
Description
Envista Holdings Corp., headquartered in Brea, California, manufactures and sells a broad range of dental products and tools and employs about 12,800 full-time staff. The company operates two reporting segments: Specialty Products & Technologies, which supplies dental implant and prosthetic systems, orthodontic products and related treatment software; and Equipment & Consumables, which provides dental office equipment, imaging and visualization systems, restorative and endodontic materials, and infection-prevention supplies. Its offerings support diagnosis, treatment and routine clinical procedures across general and specialty dental practices.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 10 | Feb 17 | NVST | Envista Holdings Corp | Envista presents strong Q4 2025 beats, positive analyst upgrades, a raised full-year guidance, robust institutional buying, and a ~24% price gain with breakout above 21-day SMA, supported by product momentum in implants and imaging, though tariff and macro risks temper short-term certainty. | Closed | -7.0% |